Back to School: How biopharma can reboot drug development. Access exclusive analysis here

MEDI-491 vaccine: Began Phase I trial of safety and immunogenicity in 20 healthy adult volunteers. Participants, in groups of four, will receive different doses

MedImmune Inc. (MEDI), Gaithersburg, Md.
Product: MEDI-491 vaccine
Indication:

Read the full 96 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE